Drug response and the development of adverse effects can vary between individuals. The use of pharmacogenomics should aid in the delivery of the right drug to the right patient, but clinical implementation of pharmacogenetic principles has been difficult, owing to a lack of randomized clinical trials that demonstrate benefit of this approach. This article reviews the use of pharmacogenetic markers in randomized clinical trials, highlighting studies related to cardiovascular disease.
- Naveen L. Pereira
- Daniel J. Sargent
- Charanjit S. Rihal
